Dog Mast Cell Tumours: Treatment and Welfare

Mast cell tumours are among the most common skin tumours in dogs, with welfare outcomes ranging from complete cure to palliative management depending on grade and location.

Key Facts

Mast cell tumours (MCTs) account for approximately 20% of all canine skin tumours
Boxers, Bulldogs, Labrador Retrievers, and Golden Retrievers are predisposed breeds
Histological grading (Kiupel 2-tier or Patnaik 3-tier) guides prognosis and treatment planning
Surgical excision with adequate margins is curative for most low-grade MCTs
Toceranib phosphate (Palladia) and masitinib target KIT mutations in high-grade disease

Welfare Considerations

Mast cell tumours can release histamine and other mediators causing systemic effects including gastric ulceration, anaphylaxis, and hypotension. Manipulation of tumours during examination or surgical planning can trigger mediator release causing acute welfare problems. Anti-histamines and gastroprotectants before surgery protect welfare. High-grade MCTs with metastatic potential require careful quality of life discussions. Complete surgical excision of low-grade tumours provides excellent welfare outcomes with high cure rates.

What You Can Do

Have any new skin lump assessed by a vet without squeezing or manipulating it
Request fine needle aspiration for rapid cytological diagnosis of suspected MCTs
Ensure adequate surgical margins are planned based on histological grade
Start famotidine and anti-histamines before surgery as recommended by your vet
Discuss staging investigations for high-grade MCTs before committing to aggressive treatment